TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
The Chinese biotech said the enrollment marks a key milestone for its advancing bile duct cancer treatment By Teri Yu Clinical-stage biotech firm TransThera Sciences (Nanjing) Inc. (2617.HK) said it…
Recent Articles
RELATED ARTICLES
-
Jacobio Pharma poised to turn a profit from precision cancer drugs
- Investors pile onto TenNor IPO with hopes for new type of gastric drug
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
- A healthy return: drug spin-off nets Keymed up to $320 million
- Eye drug maker VivaVision feels the strain in IPO funding dash
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Mega licensing deal lifts 3SBio profits but core sales slip
